Free Newsletter
Roche to change lobbyist stripes
The pharma-biotech dividing line just got a little fuzzier with Roche's plans to drop its membership in the Pharmaceutical Research and Manufacturers Association and sign on with the Biotechnology Industry Organization. After the big pharma's consumption of big biotech Genentech, the company finds that "Genentech and Roche believe BIO's purpose is closely aligned with the direction of the new company and, therefore, can represent the company's interest in Washington,'' spokeswoman Darian Wilson is quoted in a New Jersey Star Leger report. Article
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: